[{"orgOrder":0,"company":"Cantargia AB","sponsor":"Spanish Breast Cancer Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Spanish Breast Cancer Research Group","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Spanish Breast Cancer Research Group"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Immunology","graph2":"Preclinical","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Cantargia AB","highestDevelopmentStatusID":"4","companyTruncated":"Cantargia AB \/ Cantargia AB"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"CAN10","moa":"IL-1\/IL-33\/IL-36 receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0.60999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cisplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"5 Fluorouracil","moa":"||IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nadunolimab","moa":"IL-1-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CAN04","moa":"Interleukin 1 receptor accessory protein (IL1RAP)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cantargia AB \/ Undisclosed"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CAN04","moa":"Interleukin 1 receptor accessory protein (IL1RAP)","graph1":"Oncology","graph2":"Phase I","graph3":"Cantargia AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cantargia AB \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Cantargia AB \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Cantargia AB
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
